Christophe Bourdon News Today

/PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the...

Ballerup - LEO Pharma today announced that it has finalized the acquisition of the strategic asset TMB-001 as well as certain other assets from Timber Pharmaceuticals following its chapter 11...

BALLERUP, Denmark, August 28, 2023--LEO Pharma announces changes to its Global Leadership Team

LEO Pharma has acquired Timber Pharmaceuticals, in a deal that will add an ‘attractive’ late stage asset to its pipeline in medical dermatology, the company said.

/PRNewswire/ -- The Sobi® AGM was convened today on 9 May 2023. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:...

STOCKHOLM, May 9, 2023 /PRNewswire/ -- The Sobi® AGM was convened today on 9 May 2023. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows: Adoption

The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting , to be held on Tuesday, 9 May 2023 at 15.00 at IVA Konferenscenter, Grev... | March 30, 2023

Adtralza, a biologic that targets and neutralizes the interleukin (IL)-13 cytokine1, is now approved in Europe for adolescents with moderate-to-severe atopic dermatitis.2 NOT FOR DISTRIBUTION

Therapy is for the treatment of adolescents with moderate-to-severe atopic dermatitis - News - PharmaTimes

Positive CHMP opinion recommends extending use of Adtralza (tralokinumab) to adolescents (12-17 years old) in the European Union (EU) Recommendation supported by data from the Phase 3 ECZTRA